Dimed Distribuidora de Medicamentos (BSP:PNVL3) Total Receivables: R$631 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:PNVL3 Dimed SA Distribuidora de Medicamentos BSP:PNVL3
89 GF Score
Price R$11.17
GF Value R$13.64
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Dimed Distribuidora de Medicamentos Total Receivables?

Dimed Distribuidora de Medicamentos BSP:PNVL3 -1.15% 89 Total Receivables is R$631 Mil as of Mar. 2026. GuruFocus rates BSP:PNVL3 with a GF Score™ of 89/100 and a GF Value™ of R$13.64 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Dimed Distribuidora de Medicamentos's Total Receivables for the quarter that ended in Mar. 2026 was R$631 Mil.

Dimed Distribuidora de Medicamentos Total Receivables Related Terms

Dimed Distribuidora de Medicamentos Total Receivables Historical Data

* Premium members only.

The historical data trend for Dimed Distribuidora de Medicamentos's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimed Distribuidora de Medicamentos Total Receivables Chart

Dimed Distribuidora de Medicamentos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 399.46 464.73 560.35 578.00 672.05

Dimed Distribuidora de Medicamentos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 565.19 585.55 583.58 672.05 630.67
BSP:PNVL3
89GF Score
Dimed SA Distribuidora de Medicamentos BSP:PNVL3
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimed Distribuidora de Medicamentos Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of R$631 Mil mean?
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Total Receivables of R$631 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Dimed Distribuidora de Medicamentos and its competitors.
Is Dimed Distribuidora de Medicamentos' Total Receivables too high?
Dimed Distribuidora de Medicamentos' current Total Receivables is R$631 Mil. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Total Receivables compare to LLY and JNJ?
Dimed Distribuidora de Medicamentos' Total Receivables of R$631 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Dimed Distribuidora de Medicamentos and its competitors. Dimed Distribuidora de Medicamentos's current Total Receivables is R$631 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.64, compared to a current price of R$11.17 — trading 18.1% below its estimated fair value. The current Total Receivables is R$631 Mil. Dimed Distribuidora de Medicamentos' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Total Receivables is R$631 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?

Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued. The current stock price of R$11.17 is trading 18.1% below its estimated GF Value™ of R$13.64. GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.

Key valuation signals for BSP:PNVL3:

  • Total Receivables: R$631 Mil
  • GF Value™: R$13.64 vs. price of R$11.17 (18.1% below fair value)
  • GF Score™: 89/100 with 5 warning signs

No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dimed Distribuidora de Medicamentos Business Description

Address Avenida Industrial Belgraf, 865, Eldorado do Sul, RS, BRA, 92990-000
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
89GF Score

Get the complete analysis for BSP:PNVL3

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$11.17
Price
R$13.64
GF Value